CJC-1295 vs HGH (Somatropin)
Updated September 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of CJC-1295 and HGH (Somatropin) (also searched as HGH (Somatropin) vs CJC-1295) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
CJC-1295 centers on muscle, while HGH (Somatropin) leans toward muscle. On indexed research, HGH (Somatropin) is ahead (CJC-1295: 11 studies, Human clinical; HGH (Somatropin): 55, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •CJC-1295 is strongest for muscle; HGH (Somatropin) for muscle.
- •Evidence: CJC-1295 Human clinical (11 studies) vs HGH (Somatropin) Human clinical (55).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
GHRH analogue | GH/IGF-1 modulation
Growth stimulation | Growth hormone deficiency
CJC-1295 vs HGH (Somatropin): side-by-side
| Metric | CJC-1295 | HGH (Somatropin) |
|---|---|---|
| Class | Muscle | Healing |
| Regulatory status | Research use only | FDA-approved |
| Evidence grade | Human clinical | Human clinical |
| Studies indexed | 11 | 55 |
| Research level | Limited Research | FDA Approved |
| Strongest effect | Muscle & body comp | Muscle & body comp |
| Healing & recovery | 3.0 | 4.0▲ |
| Muscle & body comp | 4.0 | 5.0▲ |
| Metabolic & appetite | 3.0 | 4.0▲ |
| Neuro & mood | 2.0▲ | 2.0▲ |
| Sleep & circadian | 3.0▲ | 2.0 |
| Inflammation & immune | 2.0 | 3.0▲ |
| Skin & aesthetics | 2.0 | 4.0▲ |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | CJC-1295 | HGH (Somatropin) |
|---|---|---|
| Mechanism | GHRH (1–29) analog, modified | IGF-1 activation |
| Route | Subcutaneous injection | Subcutaneous injection |
| Half-life | ~30 min | ~20 min |
| Time to peak | — | 3–6 hours |
| Duration of action | — | variable |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is CJC-1295?
GHRH analogue used in research contexts for GH/IGF-1 modulation, muscle and bone density, sleep, and recovery.
Full CJC-1295 profile, mechanism & studies →What is HGH (Somatropin)?
HGH (somatropin) is recombinant human growth hormone, FDA-approved for pediatric and adult GH deficiency and several wasting and short-stature conditions; widely studied for body composition off-label.
Full HGH (Somatropin) profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | HGH (Somatropin) | 4.0/5 effect signal |
| Muscle | HGH (Somatropin) | 5.0/5 effect signal |
| Metabolic | HGH (Somatropin) | 4.0/5 effect signal |
| Neuro | Even | Both ~2.0/5 |
| Sleep | CJC-1295 | 3.0/5 effect signal |
| Inflammation | HGH (Somatropin) | 3.0/5 effect signal |
| Skin | HGH (Somatropin) | 4.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack CJC-1295 and HGH (Somatropin)?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
CJC-1295 vs HGH (Somatropin): side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
CJC-1295 has 11 approved studies indexed (Human clinical), and HGH (Somatropin) has 55 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is CJC-1295 or HGH (Somatropin) better?
It depends on your goal. CJC-1295 is strongest for muscle; HGH (Somatropin) for muscle. HGH (Somatropin) has more indexed studies (55). See the goal-by-goal breakdown above.
Is CJC-1295 or HGH (Somatropin) better for weight loss?
HGH (Somatropin) shows the stronger metabolic & appetite profile (4.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is CJC-1295 or HGH (Somatropin) better for muscle?
HGH (Somatropin) leads on the muscle & body-composition axis (5.0/5).
Which has more research, CJC-1295 or HGH (Somatropin)?
CJC-1295 has 11 approved studies indexed (Human clinical); HGH (Somatropin) has 55 (Human clinical). Higher counts mean more to read, not proven superiority.
Can you stack CJC-1295 and HGH (Somatropin)?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of CJC-1295 vs HGH (Somatropin)?
CJC-1295: no community-reported effects logged yet. HGH (Somatropin): none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is CJC-1295 or HGH (Somatropin) FDA-approved?
CJC-1295 is a research-use compound and is not FDA-approved. HGH (Somatropin) is FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is HGH (Somatropin) better than CJC-1295?
For muscle, HGH (Somatropin) has the edge; for muscle, CJC-1295 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed September 21, 2026.